SCYNEXIS (SCYX)
(Delayed Data from NSDQ)
$1.56 USD
-0.07 (-4.29%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.56 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value B Growth D Momentum C VGM
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 4 |
Average Target Price | $7.00 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 84 of 253 |
Current Quarter EPS Est: | -0.20 |
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 5 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/13/2024 | Maxim Group | Jason Mccarthy | Strong Buy | Strong Buy |
8/9/2024 | Cantor Fitzgerald & Co | Louise Chen | Strong Buy | Strong Buy |
3/15/2024 | Guggenheim Securities | Vamil Divan | Strong Buy | Strong Buy |
1/4/2024 | Brookline Capital Markets | Kemp Dolliver | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.